Effect of pioglitazone on inflammatory response and clinical outcome in T2DM patients with COVID-19: a randomized multicenter double-blind clinical trial

BackgroundCoronavirus disease 2019 (COVID-19) caused by the coronavirus SARS-CoV-2, has emerged as a rapidly spreading contagious disease across the globe. Recent studies showed that people with diabetes mellitus, severe obesity, and cardiovascular disease are at higher risk of mortality from COVID-...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Khaled Baagar, Thamer Alessa, Mohamed Abu-Farha, Jehad Abubaker, Heba Alhumaidi, Jose Antonio Franco Ceruto, Mohammad Khair Hamad, Ali Omrani, Salma Abdelrahman, Muhammad Zaka-Ul Haq, Abdul Wajid Safi, Bassem Alhariri, Manish Barman, Alaaeldin Abdelmajid, Humberto Vidal Denis Cancio, Eman Elmekaty, Irina Al-Khairi, Preethi Cherian, Lina Jayyousi, Mohammed Ahmed, Mohammed Qaddoumi, Sulaiman Hajji, Ahmad Esmaeel, Ali Al-Andaleeb, Arshad Channanath, Sriraman Devarajan, Hamad Ali, Thangavel Alphonse Thanaraj, Salman Al-Sabah, Fahd Al-Mulla, Muhammad Abdul-Ghani, Amin Jayyousi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-09-01
coleção:	Frontiers in Immunology
Assuntos:	COVID-19 SARS-CoV-2 inflammation type 2 diabetes pioglitazone
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1369918/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!